Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.60 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.58 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.57 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | CCR3 | P51677 | 1/20 | 0.53 |
| ▸ | UBE2M | P61081 | 1/20 | 0.53 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.53 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4231721 | 0.93 | DRD2 (0.55) | SIGMAR1PRKAA2MCHR1SLC6A12TMEM97 | |
| SCHEMBL2030049 | 0.93 | DRD2 (0.55) | SIGMAR1PRKAA2MCHR1SLC6A12TMEM97 | |
| SCHEMBL27226915 | 0.89 | SIGMAR1 (0.59) | SIGMAR1PARP1PARP2DRD3KCNA3 | |
| SCHEMBL29260128 | 0.89 | KCNA3 (0.53) | SIGMAR1PARP1PARP2DRD3KCNA3 | |
| SCHEMBL15021069 | 0.89 | SIGMAR1 (0.59) | SIGMAR1PARP1PARP2KCNA3 | |
| SCHEMBL22719510 | 0.88 | TEAD1 (0.65) | SIGMAR1PARP1PARP2UBE2MDCUN1D1 | |
| SCHEMBL1920827 | 0.88 | SIGMAR1 (0.56) | SIGMAR1MCHR1SLC6A12TMEM97PARP1 | |
| SCHEMBL30135707 | 0.88 | KCNA3 (0.52) | SIGMAR1PARP1PARP2DRD3KCNA3 | |
| SCHEMBL15021685 | 0.88 | SIGMAR1 (0.60) | SIGMAR1TMEM97PARP1PARP2KCNA3 | |
| SCHEMBL915402 | 0.88 | KMT2A (0.65) | SIGMAR1MCHR1DRD3KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339444-A1 | Methods and Compositions for Treating Fatty Liver and Viral Infections | UNIV LELAND STANFORD JUNIOR (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4525853-A1 | METHODS AND COMPOSITIONS FOR TREATING FATTY LIVER AND VIRAL INFECTIONS | The Board of Trustees of the Leland Stanford Junior University (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023225324-A1 | METHODS AND COMPOSITIONS FOR TREATING FATTY LIVER AND VIRAL INFECTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225324-A1 | METHODS AND COMPOSITIONS FOR TREATING FATTY LIVER AND VIRAL INFECTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-110938064-B | N-substituted piperidine amide derivative and use thereof | 广东东阳光药业有限公司 | 2022-12-27 | — | — | CN | disclosed |
| EP-1622914-B1 | NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | TROVIS PHARMACEUTICALS LLC (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | disclosed |
| WO-2010068881-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010068881-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-17 | — | — | WO | disclosed |
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | disclosed |
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | CCR1, CCR4, CCR5 | SIGMAR1 452/4885PRKAA2 4845/4885MCHR1 201/4885 |
| US-20250339444-A1 | Methods and Compositions for Treating Fatty Liver and Viral Infections | FABP1, FABP4, LIPC | SIGMAR1 4621/4885PRKAA2 1977/4885MCHR1 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.